GlassScriptPhysician profile
Daniel Oscar Persky
NPI 1285736033
$14,587.66
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $6,263 · 2021: $5,578 · 2022: $2,475.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $3,375.00 | 2020 | |
| Karyopharm Therapeutics INC. | $2,887.50 | 2020 | |
| Adc Therapeutics America, INC. | $2,000.00 | 2021 | |
| Genentech USA, INC. | $1,925.00 | 2021 | |
| Abbvie INC. | $1,650.00 | 2022 | |
| Beigene USA, INC. | $953.33 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $825.00 | 2022 | |
| Lilly USA, LLC | $700.00 | 2021 | |
| Seagen INC. | $99.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $97.85 | 2019 | |
| Gilead Sciences, INC. | $35.38 | 2019 | |
| Amgen INC. | $26.32 | 2019 | |
| Kite Pharma, INC. | $13.28 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Research and ownership
$3,024.27 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Persky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.